Feature Opinion Story: WHY ONCY’s Pela is the Broad Activator Platform Big Pharma Needs for Durable Results

  

Market Talk 

The possibility of a government shutdown is back on the table. In times like this, traders often rotate toward safety. Gold and silver names like KGC and HL can catch flows as havens, while perhaps speculative activity and volume in now penny stock ONCY has been picking up with its new PDAC trial plans.

Markets can get choppy in these moments, so staying nimble elsewhere may make some sense.

Stock Talk

KGC & HL – Gold and silver miners remain front and center, each with their own strengths in a world of growing demand. Back-of-the-envelope math points to the real possibility of both stocks doubling from here.

Ramaco (METC) – METC brings a combined met coal and rare earths angle. METCB tracks the rare earth progress directly, while METCI offers an 8.25% preferred dividend — a steady yield to complement the growth side.  Maybe "some" - feel like mainstays for these times.

    

Feature

One in Four Isn't enough - Why Pela Could Expand current treatments 

From polio labs to today’s trials, Pelareorep shows signs of powering treatments across cancers.

Pelareorep’s story starts not in a corporate lab, but in nature. The reovirus has circulated quietly among humans for decades, often causing no symptoms at all. Back in the 1950s, Dr. Albert Sabin, best known for developing the oral polio vaccine, noted the virus’s unusual behavior in cancer cells and claimed its discovery in that context. Decades later, scientists like Dr. Patrick Lee unlocked its potential as an oncolytic virus. Oncolytics Biotech Inc. (ONCY) has since turned it into a clinical therapy: pelareorep, a safe, IV-delivered version designed to amplify what casual reovirus exposure could never accomplish on its own — infiltrating tumors, cracking open and lysing cancer cells, and opening the door for the immune system to rush in.

Once inside, Pela sparks an immune cascade. Tumor cells break apart, antigens spill out, and T-cells begin replicating and swarming into cancers that were previously cold and invisible to the immune system. Safety has been shown across years of small trials, but more importantly, so have signals of effect: breast cancer patients in IND-213 lived longer, pancreatic patients have shown a 62% response rate including a complete response, and activity has been reported in colorectal and KRAS-mutant cancers. The evidence keeps pointing in one direction — Pela doesn’t just slip safely into patients, it leaves behind immune activation where none existed before.

ONCY Is Planning Ahead

ONCY isn’t standing still. A new PDAC registration trial is already being planned to press the advantage from years of safety data and immune activation signals.

If retail can see it, Big Pharma may be seeing it too. And perhaps one of them will seize the opportunity to take the mantle of advancing Pela — not in piecemeal, but in a bigger and broader manner, as part of the Trinity Approach.

The planned PDAC registration trial could also be the opening for Merck. Keytruda is their crown jewel, yet in pancreatic cancer it helps only a fraction of patients. Pela’s ability to wake the immune system could expand Keytruda’s reach — turning cold tumors hot. And perhaps the cleanest path would be for Merck to take over and hold ONCY as a subsidiary, bringing not just the resources to run broader trials, but also their arsenal of checkpoint inhibitors and ADCs to integrate with the immune-based Pela platform.

At present, checkpoint drugs, ADCs, and targeted plays are only pieces of the mechanism. Without the spark of immune activation, they fall short — helping only about one in four patients. Pela could be that ignition — the platform inside a broader Trinity Approach that expands their reach across cancers, potentially opening significant and durable responses for over 190,000 additional patients in the U.S. each year who today see little benefit.

Conclusion

And that’s the point. Big Pharma keeps building fancy engines for niche cases, but without the spark plug of Pela, they risk stalling — because it’s Pela that can more broadly crack open cancer cells, activate the immune system, and make tumors visible so the other expensive agents can actually work synergistically with Pela to foster more durable results. For small investors, the Jones way on spec stocks still applies — maybe some, not too much, or even none. Just enough to keep it fun.

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare !

For now, we close by noting that any view on the market and stocks on any particular day may change in the future days to come. That is why we watch and see how our views match up with the reality of the time.  But trying to look ahead a few months into the future may be a way to do things.  If you think too deep about world events and the recent alliances forming, projecting ahead can be a dicey endeavor.  In all -  we use the word maybe "some", not "too much" and play it accordingly.  Remember, never get arrogant in our various notions because things do change in the market and individual stocks are subject to many factors outside of our control.. So we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.This site does NOT make Buy / Sell recommendations.
________

Mainstays that could well DOUBLE and a Spec stock on a Trinity note: ONCY with Merck?

 

Market Talk 

Although markets have climbed, stocks are still chopping sideways as they trade based on factors and dynamics tied to each sector and each company. But on the equity side, a few names continue to stand out.

 Stock Talk

KGC & HL – Gold and silver miners remain front and center, each with their own strengths in a world of growing demand. Back-of-the-envelope math points to the real possibility of both stocks doubling from here.

Ramaco (METC) – METC brings a combined met coal and rare earths angle. METCB tracks the rare earth progress directly, while METCI offers an 8.25% preferred dividend — a steady yield to complement the growth side.  Maybe "some" - feel like mainstays for these times.

    

Spec Stock Corner

ONCY – A different kind of story. It feels deal-dependent.  The Trinity Approach that's been missing a piece to increase the odds of surviving cancer.

https://stockstowatch.blogspot.com/2025/09/the-trinity-missing-puzzle-piece-to.html

The recent KRAS update has renewed visibility, and the Trinity Approach notion — with ONCY’s Pela as the lead immune agent — highlights why, one of several big Phama's - Merck could be the natural fit. Merck already owns the world’s top checkpoint inhibitor (CI) in Keytruda and has built a serious pipeline of antibody–drug conjugates (ADCs). Pela could slot in as the missing immune leg to strengthen their regimens — and with Merck’s infrastructure, a fast track into Phase 3 becomes realistic.

Some will say maybe, some will say no — but who really knows what goes on in the backrooms of big pharma. What’s clear is that one major player could be first to step up, fill the missing piece, and make the Trinity Approach stand out as a real cancer treatment. A buyout value north of $6/share isn’t unreasonable — maybe even better than a 5x gainer. But when it comes to spec — maybe some, maybe none, but not too much is a way we think here.

Another Spec: MOJO – As a footnote, Equator Beverage Company (MOJO) stock. Thinly traded, under-a-buck OTC issue tied to a no-frills, refreshing coconut water drink. They’ve reported positive earnings and even bought back stock. We keep a case or two here (and just a few shares) simply because we like it.

Spec stocks are viewed here as “maybe some or none” — not too much, just enough to keep it fun. Keep an eye on all your stocks, invest and trade according to your own game plan and appetite for risk, and always stay aware.

__

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare !

For now, we close by noting that any view on the market and stocks on any particular day may change in the future days to come. That is why we watch and see how our views match up with the reality of the time.  But trying to look ahead a few months into the future may be a way to do things.  If you think too deep about world events and the recent alliances forming, projecting ahead can be a dicey endeavor.  In all -  we use the word maybe "some", not "too much" and play it accordingly.  Remember, never get arrogant in our various notions because things do change in the market and individual stocks are subject to many factors outside of our control.. So we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.This site does NOT make Buy / Sell recommendations.
________

Jones Notes on Stocks to Watch

  

Market Talk 

Inflation remains sticky and tariffs add uncertainty, while the Fed is signaling concern about rising unemployment. That mix makes rate cuts likely, even as growth softens — the kind of backdrop that often fuels stagflation worries. In that environment, hard assets shine. Gold tends to outperform when inflation runs hot and stocks stumble, while silver, its high-beta cousin, often delivers sharper moves once the bid arrives.

On the equity side, gold and silver miners are still front and center — Kinross Gold (KGC) and Hecla Mining (HL) (scroll back to prior posts). Both have strengths in a world of growing demand, and both are benefiting from renewed interest in hard-asset exposure.

 Stock Talk

KGC and HL remain core mining names, but other materials deserve a look. Ramaco Resources (METCB) ties into the Brook Mine rare earths potential, (with a maybe some of the more volatile METC) while its high dividend preferred (METCI) pays investors to wait.

Meanwhile, in tech, Lam Research (LRCX), HPE, and Intel (INTC) all sit at the crossroads of semiconductors and AI build-outs — a sector still volatile but where equipment and infrastructure names have room to run as data-center demand expands.

Russian drones over Poland and now Romania are making the kinds of advanced systems that KTOS is developing here in the US more visible by those who pay attention.

Some Spec Stocks of Note:

Oncolytics Biotech (ONCY) has gained fresh visibility from the KRAS MSS update and growing awareness of the Trinity approach — the potential of Pela as the third leg alongside checkpoint inhibitors and targeted ADCs. Still, the near trading action looks deal-dependent, with a partner or buyout likely needed to escape the “old ways” of biotech drift.

What can’t be overlooked is that KRAS mutant MSS cancers span across many tumor types. Abnormal cell multiplication in KRAS cancers has long been one of the hardest challenges in oncology. That makes it difficult for Big Pharma to ignore.

A deal to bring Pelareorep into their fold — alongside checkpoint inhibitors and ADCs — seems very possible. Whether that happens soon may hinge both on escaping the old patterns that weigh down small-cap biotech and on the new CEO’s mission-driven push to get a deal done.

Opendoor (OPEN), while risky and shorted, has shown how new management with bold ideas — and lower rates — can spark both investors and meme-style bursts. A theme that could persist if the Fed eases further.

And as a footnote — Equator Beverage Company (MOJO) stock. Thinly traded, under-a-buck OTC issue tied to a no-frills, refreshing coconut water drink. They’ve reported positive earnings and even bought back stock. We keep a case or two here (and just a few shares) simply because we like it.

Spec stocks are viewed here as “maybe some or none” — not too much, just enough to keep it fun. Keep an eye on all your stocks, invest and trade according to your own game plan and appetite for risk, and always stay aware.

__

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare !

For now, we close by noting that any view on the market and stocks on any particular day may change in the future days to come. That is why we watch and see how our views match up with the reality of the time.  But trying to look ahead a few months into the future may be a way to do things.  If you think too deep about world events and the recent alliances forming, projecting ahead can be a dicey endeavor.  In all -  we use the word maybe "some", not "too much" and play it accordingly.  Remember, never get arrogant in our various notions because things do change in the market and individual stocks are subject to many factors outside of our control.. So we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.This site does NOT make Buy / Sell recommendations.
________

The Trinity: The Missing Puzzle Piece to Fight Cancer — Update: Watch ONCY

  

Part 2:  The Trinity Approach 

New colorectal results — backed by pancreatic and breast cancer signals — show how Pela may be the missing piece that makes checkpoint inhibitors finally work where they’ve fallen short.

Top Line – Quick Read

ONCY’s new colorectal data may be exploratory, but the impact is hard to miss. KRAS-mutant MSS colorectal cancer is one of the toughest oncology populations, making up roughly 35–40% of all colorectal cases — about 50–60,000 patients every year in the U.S. and nearly 700,000 worldwide. Using just checkpoint inhibitors has fallen short here without the immune agent that Pela fits into like the missing puzzle piece. Pela changes that equation: flipping tumors from cold to hot, opening the door for checkpoint inhibitors to finally work. Seeing PFS nearly tripled and OS more than doubled isn’t just numbers — it signals improved and longer life, and within the Trinity framework — CI, ADC, and Pela — perhaps even the possibility of durable remission, or even a cure...

The Trinity Mechanisms Explained

Yesterday’s PR on new colorectal (KRAS-mutant MSS) results adds weight to the Trinity Approach, alongside earlier pancreatic cancer signals and supportive breast cancer data. We’ve been tracking this framework — three mechanisms that big pharma could already be sketching on their planning boards, waiting for more validation. Here’s how each part works, and why today’s data matters:

• Checkpoint Inhibitors (CI): block certain proteins (like PD-1) that tumors use as a shield to suppress the T-cell attack. This opens the doors for Pela to attack.

• Antibody–Drug Conjugates (ADCs): deliver precision-targeted antibody and chemo payloads, less harshly than traditional chemotherapy.

• Pelareorep (Pela): infiltrates cold tumors, replicates inside cancer cells, and triggers their death. At the same time, it flips the immune switch — multiplying T-fight cells, building memory T-cells, and turning the tumor from invisible to inflamed. This priming effect is what makes checkpoint inhibitors and ADCs hit harder.

The new colorectal results just announced add more validation that Pela has something real.

Stock Talk – Combo Power

As we outlined in the last report, the Trinity isn’t just three lanes running parallel — it’s about the combos:

• CI + Pela: immune shields removed, tumors primed, stronger immune attack.

• ADC + Pela: payloads delivered into tumors already sensitized, hitting harder with less collateral damage.

• CI + ADC + Pela: the full integration — immune priming, checkpoint release, and precision kill.

What’s different now is that Pela’s role just got more validated with the new colorectal results just announced. That shifts it from “hypothetical partner” to “credible force multiplier” for the big pharma players we already highlighted.

Investor Lens – Odds Reset

The new colorectal data just announced comes from a subgroup exploratory trial, so it isn’t the final word. But even at this stage, seeing PFS nearly tripled and OS more than doubled is a signal with potentially huge impact — especially in a population where using just checkpoint inhibitors has fallen short without the immune agent that Pela fits into like the missing puzzle piece.

That moves Pela up a notch. For investors, the angle isn’t ONCY proving it can stand alone — it’s that the data raises the odds of buyout or partner interest from big pharma. ONCY now carries somewhat less speculative risk with potential upside, possibly significant if the stars line up.

It remains a “maybe” — to see if ONCY management can maximize potential or languish in the old-guard ways of the past.

Why the New Colorectal Results Matter

KRAS-mutant MSS colorectal cancer is one of the hardest-to-treat groups in oncology. Roughly 40–45% of all colorectal cancers are KRAS-mutant, and most of those are MSS. That works out to about 35–40% of all CRC cases — or 50,000–60,000 new patients every year in the U.S. and ~700,000 worldwide. Using just checkpoint inhibitors has fallen short here without the immune agent that Pela fits into like the missing puzzle piece.

Pela changes that equation. By flipping tumors from cold to hot, Pela can make checkpoint inhibitors work in this population for the first time. That’s why PFS nearly tripling and OS more than doubling isn’t just numbers — it’s impact. It is not hyperbole to say the potential is improved and longer life, and within the Trinity framework — CI, ADC, and Pela — maybe even the chance for durable remission, or even a cure.

The new data makes ONCY’s Pelareorep harder to ignore — and seems to put ONCY at square one directly on center stage.  Large pharma is on the hunt for missing pieces that fit into current regimens safely — and Pelareorep now looks more like one that may deliver relative safety and synergistic effectiveness.

___

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare !

For now, we close by noting that any view on the market and stocks on any particular day may change in the future days to come. That is why we watch and see how our views match up with the reality of the time.  But trying to look ahead a few months into the future may be a way to do things.  If you think too deep about world events and the recent alliances forming, projecting ahead can be a dicey endeavor.  In all -  we use the word maybe "some", not "too much" and play it accordingly.  Remember, never get arrogant in our various notions because things do change in the market and individual stocks are subject to many factors outside of our control.. So we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.This site does NOT make Buy / Sell recommendations.
________

Special Report: The Trinity Approach: Combining What Big Pharma Has - With What It Needs - and Watch ONCY

  

Market Talk 

Inflation is proving sticky and new tariffs add uncertainty, while the Fed has also signaled concern about rising unemployment. That mix makes it likely the Fed will reduce interest rates, even as growth softens — the kind of backdrop that carries the early signs of stagflation. In that environment, hard assets shine. Gold historically outperforms when inflation runs hot and stocks stumble, while silver, the high-beta cousin, delivers bigger swings once the bid shows up.

HL and KGC remain at the forefront in this cycle — steady names in the metals space, less speculative, and still positioned to benefit

Stock Talk

Sometimes special situations arise where it can pay to stay aware — smaller, riskier names with the potential to deliver outsized reward. One such idea is newly described here: the Trinity Approach — combining what big pharma already has with what it still needs. That’s where ONCY comes into focus.

The Trinity Approach: Combining What Big Pharma Has - With What It Needs

Pelareorep, from Oncolytics Biotech (ONCY), is an oncolytic virus that can flip cold tumors hot — drawing in T-cells and expanding immune clones.

Johnson & Johnson paid $2B to acquire Ambrx for its ADC (Antibody–Drug Conjugate) pipeline, but they still lack a checkpoint inhibitor. Pela could be the missing ignition switch of this story — and J&J remains the natural name investors focus on first, given their recent moves and position in the field.

But here’s where the story widens. Roche, AstraZeneca, Pfizer, and even both Merck's already control the full CI (Checkpoint Inhibitor) + ADC arsenal. Add Pela, and suddenly the Trinity Approach comes into view: checkpoint inhibitor + ADC + pelareorep.

That’s a three-part cocktail with the potential to change the game — and the pharma that moves first could own the space.

---

Pelareorep: The Add-On Platform for CI + ADC Regimens

Pelareorep, from Oncolytics Biotech (ONCY), is an oncolytic virus that can turn cold tumors hot — boosting PD-L1 (programmed death-ligand 1), drawing in CD8 T cells, and expanding tumor-specific clones. Pelareorep is a clinically manufactured form of reovirus, delivered by IV. It seeks out cancer cells, which often have weakened antiviral defenses, and replicates inside them until the cells burst. That not only kills the tumor cells directly but also releases signals that call in the immune system — flipping ‘cold’ tumors into ‘hot’ ones that immune T-cells can now attack. More than a single drug, it functions as an immune ignition switch.

J&J’s $2B Ambrx buyout gave them ADC assets, but without a CI, Pela would be one way to strengthen their franchise. J&J remains the natural name investors focus on first. Think Pela paired with Ambrx’s assets:

• Pela + ARX517 (PSMA, prostate)

• Pela + ARX788 (HER2, breast)

• Pela + ARX305 (CD70, kidney/lymphoma)

And yet another case can be made for a Trinity Approach with those who already hold both CIs and ADCs under one roof. That’s where Pela could become the ignition switch for an entire class of regimens:

Combo Map:
(Examples current as of 2025 — based on publicly available pipelines and marketed drugs)

• Roche → Tecentriq (CI) + Kadcyla/Polivy (ADCs) + Pela

• AstraZeneca → Imfinzi (CI) + Enhertu/Dato-DXd (ADCs) + Pela

• Pfizer/Seagen → Bavencio (CI) + Padcev/Adcetris/Tivdak (ADCs) + Pela

• Merck US → Keytruda (CI) + ADC pipeline + Pela

• Merck KGaA (Germany) → Bavencio (CI) + ADC programs + Pela

• Johnson & Johnson → On paper they look like the odd one out without a checkpoint inhibitor. But add Pela to their Ambrx ADCs, and suddenly they’re holding the ignition switch in this story — what looks like a gap today could become tomorrow’s advantage, and they might move before rivals even notice.

ONCY’s long road has frustrated investors and raised eyebrows, but that persistence also means Pela is one of the few immune primers with both safety and early efficacy signals established.

Here’s the potential synergy: ADCs deliver the guided strike, CIs release the immune brakes, and Pela lights the tumor on fire to rally T-cells. Together, that’s a natural triple play: precision kill + brake release + immune ignition. And Pela isn’t limited to these pairings — its immune ignition can be layered onto almost any treatment, from chemo to radiation, making it a modular plug-in across oncology.

In engineering, a triangle is the strongest shape — three points form a stable structure where two alone can wobble and fail. By analogy, combining all three may cover the weaknesses of each, and this Trinity could be the way — with the combined strengths overcoming the wages that cancer takes, offering greater hope where single agents have fallen short.

---

Investor Lens

ONCY trades around a buck — priced as if nothing matters. After decades of slow roll, some investors remain skeptical, and dilution risk is real. As for a buy? There’s a saying we use to handle risk: “Maybe some, but not too much.” And sometimes, in this game, some turns out to be more than enough if the story plays out.

---

Conclusion

Pelareorep has lived a long and frustrating journey, leaving some investors skeptical. Years of trials, dilution, and slow progress have made the proof process painful. Yet the Trinity Approach reframes Pela not as a standalone hope, but as the missing piece that could complete what pharma already has in checkpoint inhibitors and ADCs. The logic is straightforward: three points form strength where two can fail.

This doesn’t erase the risks — biotech always carries them — but it does give the story shape — a kind of blueprint for how these tools might fit together. It’s about how these agents work together — the kind of integration that could define the next big thing in oncology, worth multiple billions over time to whichever company takes the lead. After years of endurance, the question may not be whether the Trinity can be proven, but who will be first to take action.

__

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare !

For now, we close by noting that any view on the market and stocks on any particular day may change in the future days to come. That is why we watch and see how our views match up with the reality of the time.  But trying to look ahead a few months into the future may be a way to do things.  If you think too deep about world events and the recent alliances forming, projecting ahead can be a dicey endeavor.  In all -  we use the word maybe "some", not "too much" and play it accordingly.  Remember, never get arrogant in our various notions because things do change in the market and individual stocks are subject to many factors outside of our control.. So we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.This site does NOT make Buy / Sell recommendations.
________

GOLD and SILVER in the Spotlight and :STAY TUNED for a Special ALERT Report on yet another early opp - coming soon !

  

Market Talk 

Inflation is proving sticky and new tariffs add uncertainty, while the Fed has also signaled concern about rising unemployment. That mix makes it likely the Fed will reduce interest rates, even as growth softens — the kind of backdrop that carries the early signs of stagflation. In that environment, hard assets shine. Gold historically outperforms when inflation runs hot and stocks stumble, while silver, the high-beta cousin, delivers bigger swings once the bid shows up.

Stock Talk

Now add in AI. As noted in our previous post, the new AI data centers are electricity hogs, and to keep regulators happy they’re being paired with massive solar farms. Every solar panel uses silver paste hardened into grid lines and contacts — and silver is the most conductive metal of all. Each gigawatt of solar consumes about 750,000 ounces of silver. Meta’s Louisiana project alone adds over 1M ounces a year, nearly 1% of global demand from a single site. Scale that across the global AI build-out and silver has a structural new tailwind just as stagflation pressure builds.

Two stocks stand out. Hecla (HL) is the largest U.S. silver producer, with low costs thanks to gold, zinc, and lead by-products. Every $5 move in silver flows straight into EPS, and at $45–50 silver HL could top $1/share versus pennies a year ago. Kinross (KGC) is a gold cash-flow machine, with all-in costs near $1,300–1,400/oz. Every $100 rise in gold feeds directly into profits, and if gold grinds toward $3,700–4,000/oz, KGC looks cheap relative to peers.

BOTTOM LINE: With the Fed likely to cut rates into sticky inflation, gold and silver look set to regain the spotlight. HL is the silver lever, KGC the gold engine — both undervalued if this setup plays out.

_________________________

Special Alert  

The Jones Report has a new opportunity "of some" being described on the drafting table with the potential for BIG impact. Sometimes the next big wave isn’t obvious until the pieces line up. As soon as the ink is dry, you’ll read it here first. Coming soon — don’t miss it.

__

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare !

For now, we close by noting that any view on the market and stocks on any particular day may change in the future days to come. That is why we watch and see how our views match up with the reality of the time.  But trying to look ahead a few months into the future may be a way to do things.  If you think too deep about world events and the recent alliances forming, projecting ahead can be a dicey endeavor.  In all -  we use the word maybe "some", not "too much" and play it accordingly.  Remember, never get arrogant in our various notions because things do change in the market and individual stocks are subject to many factors outside of our control.. So we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.This site does NOT make Buy / Sell recommendations.
________